BRPI0406596A - Métodos para tratar a dor articular e melhorar o sono utilizando um agonista/antagonista de estrogênio - Google Patents

Métodos para tratar a dor articular e melhorar o sono utilizando um agonista/antagonista de estrogênio

Info

Publication number
BRPI0406596A
BRPI0406596A BR0406596-4A BRPI0406596A BRPI0406596A BR PI0406596 A BRPI0406596 A BR PI0406596A BR PI0406596 A BRPI0406596 A BR PI0406596A BR PI0406596 A BRPI0406596 A BR PI0406596A
Authority
BR
Brazil
Prior art keywords
methods
joint pain
antagonist
estrogen agonist
improving sleep
Prior art date
Application number
BR0406596-4A
Other languages
English (en)
Inventor
Charles David Petrie
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of BRPI0406596A publication Critical patent/BRPI0406596A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Anesthesiology (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

"MéTODOS PARA TRATAR A DOR ARTICULAR E MELHORAR O SONO UTILIZANDO UM AGONISTA/ANTAGONISTA DE ESTROGêNIO". A presente invenção fornece métodos, composições farmacêuticas e estojos para tratar a dor articular e/ou melhorar o sono com utilização de um SERM de fórmula (I): em que as variáveis A, B, D, E e G, Y e Z¬ 1¬ são da forma definida na especificação.
BR0406596-4A 2003-01-22 2004-01-09 Métodos para tratar a dor articular e melhorar o sono utilizando um agonista/antagonista de estrogênio BRPI0406596A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US44183003P 2003-01-22 2003-01-22
PCT/IB2004/000093 WO2004064832A2 (en) 2003-01-22 2004-01-09 Methods for treating joint pain or improving sleep using an estrogen agonist/antagonist

Publications (1)

Publication Number Publication Date
BRPI0406596A true BRPI0406596A (pt) 2005-12-20

Family

ID=32771981

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0406596-4A BRPI0406596A (pt) 2003-01-22 2004-01-09 Métodos para tratar a dor articular e melhorar o sono utilizando um agonista/antagonista de estrogênio

Country Status (8)

Country Link
US (1) US20040152713A1 (pt)
EP (1) EP1599199A2 (pt)
JP (1) JP2006516276A (pt)
BR (1) BRPI0406596A (pt)
CA (1) CA2513432A1 (pt)
MX (1) MXPA05007771A (pt)
TW (1) TW200505896A (pt)
WO (1) WO2004064832A2 (pt)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060198872A1 (en) * 2005-03-07 2006-09-07 Chioma Ikonte Plant based dietary supplement for improving the duration and quality of sleep
US20070099882A1 (en) * 2005-10-27 2007-05-03 Gurney Harry C Methods and compositions for prolonged alleviation of articular joint pain
US20100048713A1 (en) * 2006-01-06 2010-02-25 Aarhus Universitet Compounds acting on the serotonin transporter
CA2654445A1 (en) * 2006-06-05 2007-12-13 Auspex Pharmaceuticals, Inc. Preparation and utility of substituted imidazopyridine compounds with hypnotic effects
US20070298117A1 (en) * 2006-06-23 2007-12-27 The Procter & Gamble Company Compositions and kits comprising a melatonin component and a chondroprotective component
US8653066B2 (en) 2006-10-09 2014-02-18 Charleston Laboratories, Inc. Pharmaceutical compositions
EP2240022B1 (en) 2008-01-09 2016-12-28 Charleston Laboratories, Inc. Bilayered tablets comprising oxycodone and promethazine
EP2451274B1 (en) 2009-07-08 2017-10-04 Charleston Laboratories, Inc. Pharmaceutical compositions
US8853423B2 (en) 2010-06-17 2014-10-07 Seragon Pharmaceuticals, Inc. Indane estrogen receptor modulators and uses thereof
EP2793853B1 (en) * 2011-12-23 2015-12-16 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Pharmaceutical formulations of flurbiprofen and glucosamin
WO2014114786A1 (en) * 2013-01-28 2014-07-31 Sanovel Ilac Sanayi Ve Ticaret A.S. Pharmaceutical combinations of flurbiprofen, glucosamin and capsaicin
CA3042642A1 (en) 2013-08-12 2015-02-19 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
WO2015095391A1 (en) 2013-12-17 2015-06-25 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
DK3169315T3 (da) 2014-07-17 2020-08-10 Pharmaceutical Manufacturing Res Services In Væskefyldt doseringsform til forhindring af misbrug med øjeblikkelig frigivelse
AU2015336065A1 (en) 2014-10-20 2017-05-04 Pharmaceutical Manufacturing Research Services, Inc. Extended release abuse deterrent liquid fill dosage form
WO2016107894A1 (en) * 2014-12-31 2016-07-07 Sanovel Ilac Sanayi Ve Ticaret A.S. Composition for joint and cartilage disorders comprising flurbiprofen, glucosamine sulfate, chondroitin sulfate, hyaluronic acid and methylsulfonylmethane
US10179109B2 (en) 2016-03-04 2019-01-15 Charleston Laboratories, Inc. Pharmaceutical compositions comprising 5HT receptor agonist and antiemetic particulates
US20210282706A1 (en) 2020-03-16 2021-09-16 Koninklijke Philips N.V. Characterizing stimuli response to detect sleep disorders

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5552412A (en) * 1995-01-09 1996-09-03 Pfizer Inc 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis
TW442286B (en) * 1996-02-28 2001-06-23 Pfizer New therapeutic uses of estrogen agonists
US5780497A (en) * 1996-04-19 1998-07-14 American Home Products Corporation 2-phenyl-1- 4-(amino-1-yl-alk-1-ynyl)-benzyl!-1H-indol-5-ols as estrogenic agents
US5998402A (en) * 1996-04-19 1999-12-07 American Home Products Corporation 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indoles as estrogenic agents
US5985910A (en) * 1996-04-19 1999-11-16 American Home Products Corporation 3- [4- (2- Phenyl-Indole-1-ylmethyl) Phenyl]- Acrylamides as estrogenic agents
US5880137A (en) * 1996-04-19 1999-03-09 American Home Products Corporation 2-phenyl-1- 4-(amino-1-yl-alk-1-ynyl)-benzyl!-1H-indol-5-ols as estrogenic agents
US5958418A (en) * 1997-01-22 1999-09-28 Johnson Prillerman; Kathleen O. External herbal composition for treating muscle aches and joint pain
JP3766165B2 (ja) * 1997-03-07 2006-04-12 株式会社ニコン 画像形成方法及び感光材料
CA2267049A1 (en) * 1999-02-05 2000-08-05 Bioglan Laboratories Ltd. Pharmaceutical compositions
CO5271709A1 (es) * 2000-01-12 2003-04-30 Pfizer Prod Inc Composiciones y procedimientos para el y tratamiento de afecciones que responden a estrogenos
EP1192945A3 (en) * 2000-09-21 2004-03-03 Pfizer Products Inc. Use of an estrogen agonist/antagonist for treating osteoarthritis

Also Published As

Publication number Publication date
WO2004064832A3 (en) 2004-12-16
TW200505896A (en) 2005-02-16
JP2006516276A (ja) 2006-06-29
EP1599199A2 (en) 2005-11-30
WO2004064832A2 (en) 2004-08-05
CA2513432A1 (en) 2004-08-05
US20040152713A1 (en) 2004-08-05
MXPA05007771A (es) 2005-09-30

Similar Documents

Publication Publication Date Title
BR0316350A (pt) Diaminotriazóis úteis como inibidores de proteìna cinases
BR0313160A (pt) Composto, composição farmacêutica, métodos para tratar uma condição e um neoplasmo suscetìvel em um animal em um animal, processo para preparar um composto e uso de um composto
BRPI0717907A2 (pt) "composto, composição farmacêutica, métodos para tratar um câncer, para inbir ou modular a atividade da lipídeo quinase, processo para a produçãoo de uma composição farmacêutica, uso de um composto e kit"
BRPI0715746B8 (pt) composto ou sal farmaceuticamente aceitável do mesmo e composição farmacêutica os compreendendo
BR0309343A (pt) Composto, composição farmacêutica, uso de um composto, e, método de tratamento ou profilaxia de doenças ou condições humanas
BRPI0515483A (pt) derivados heterocìclicos para o tratamento de doenças mediadas por enzimas estearoil-coa desaturase
EP2114925A4 (en) AZETIDINE ANALOGUE AIS NUCLEOSIDASE AND PHOSPHORYLASE HEMMER
BRPI0510500B8 (pt) formulação de pó seco, seu método de preparação e dispositivo de inalação de pó seco
BR0316375A (pt) Diazinopirimidinas
BR0310092A (pt) Combinação de compostos orgânicos
BRPI0510515A (pt) compostos de morfolina
BR0209127A (pt) compostos, composições farmacêuticas, métodos para o tratamento de dores, métodos para a modulação de uma resposta farmacológica e usos de compostos
BRPI0415683A (pt) inibidores da reabsorção de norepinefrina para o tratamento de distúrbios do sistema nervoso central
BR0209129A (pt) Compostos, composições farmacêuticas, métodos para tratamento de dores, métodos para modulação de uma resposta farmacológica e usos de compostos
BRPI0516483A (pt) preparo e uso de derivados de ácido bifenil-4-il-carbonilamino para o tratamento de obesidade
BR0309342A (pt) Composto, composição farmacêutica, uso de um composto, e, método de tratamento ou profilaxia de doenças ou condições humanas
BRPI0515577A (pt) compostos de carbonila que podem ser empregados como inibidores de fator xa de coagulação
BRPI0606675A2 (pt) agonista receptor de neuropeptìdio-2, composições farmacêuticas que compreendem o mesmo, compostos, método para o tratamento terapêutico e/ou profilático de enfermidades e utilização dos compostos
BR0313624A (pt) Agonismo do receptor 5ht2a para tratamento da disfunção termo-regulatória
MXPA05007771A (es) Procedimientos de tratamiento del dolor articular o para mejorar el sueno usando un agonista/antagonista de estrogeno.
BRPI0414948A (pt) derivados de pirazolo-e-imidazo pirimidina
BR0316723A (pt) Derivados de anilinopirazol úteis para o tratamento de diabetes
BRPI0508051A (pt) derivados de heteroarilaminopirazol utilizáveis para o tratamento de diabetes
BRPI0511722A (pt) 3-amino-1-arilpropilindóis como inibidores da recaptação de monoamina
BRPI0416030A (pt) pirido-7-pirimidin-7-onas substituìdas com hidroxialquila

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 4A, 5A, 6A, 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2159 DE 22/05/2012.